Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

The role of cholecalciferol supplementation in end-stage renal disease (ESRD) patients has been questioned.

Who Took Part

By PubMed's age tags, the people studied were older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

Vascular calcifications were assessed by lateral X-ray radiography.

What Was Measured

Topics PubMed links to this paper include Bone Density Conservation Agents, Calcium, Cholecalciferol, Dietary Supplements, Glomerular Filtration Rate, Kidney Failure, Chronic and Parathyroid Hormone.

Author keywords: calcification, parathormone and vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc and Parathyroid Hormone (PTH 1-84).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2013 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Vitamin D, K2, Magnesium and Zinc compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.